|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/19 CASI Pharmaceuticals, Inc. 10-K 12/31/18 91:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 592K
2: EX-10.20 Material Contract HTML 25K
3: EX-10.21 Material Contract HTML 31K
4: EX-10.22 Material Contract HTML 34K
5: EX-10.23 Material Contract HTML 69K
6: EX-10.24 Material Contract HTML 50K
7: EX-10.25 Material Contract HTML 152K
8: EX-10.26 Material Contract HTML 90K
9: EX-21 Subsidiaries List HTML 21K
10: EX-23.1 Consent of Experts or Counsel HTML 25K
11: EX-23.2 Consent of Experts or Counsel HTML 25K
12: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
13: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
14: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
15: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
22: R1 Document and Entity Information HTML 59K
23: R2 Consolidated Balance Sheets HTML 105K
24: R3 Consolidated Balance Sheets [Parenthetical] HTML 44K
25: R4 Consolidated Statements of Operations and HTML 65K
Comprehensive Loss
26: R5 Consolidated Statements of Stockholders' Equity HTML 77K
27: R6 Consolidated Statements of Cash Flows HTML 117K
28: R7 Description of Business HTML 60K
29: R8 Summary of Significant Accounting Policies HTML 75K
30: R9 Acquisition of Abbreviated New Drug Applications HTML 40K
From Sandoz
31: R10 Acquisition of Abbreviated New Drug Application HTML 29K
From Laurus Labs
32: R11 Investment in Equity Securities HTML 54K
33: R12 Property and Equipment HTML 61K
34: R13 Intangible Assets HTML 63K
35: R14 Establishment of Casi Wuxi HTML 27K
36: R15 Note Payable HTML 28K
37: R16 Stockholders' Equity HTML 90K
38: R17 Employee Retirement Plan HTML 28K
39: R18 Stock-Based Compensation HTML 310K
40: R19 Income Taxes HTML 173K
41: R20 Fair Value Measurements HTML 132K
42: R21 Related Party Transactions HTML 32K
43: R22 License Arrangements HTML 33K
44: R23 Commitments and Contingencies HTML 52K
45: R24 Subsequent Event HTML 27K
46: R25 Summary of Significant Accounting Policies HTML 116K
(Policies)
47: R26 Acquisition of Abbreviated New Drug Applications HTML 33K
From Sandoz (Tables)
48: R27 Investment in Equity Securities (Tables) HTML 48K
49: R28 Property and Equipment (Tables) HTML 59K
50: R29 Intangible Assets (Tables) HTML 63K
51: R30 Stockholders' Equity (Tables) HTML 76K
52: R31 Stock-Based Compensation (Tables) HTML 304K
53: R32 Income Taxes (Tables) HTML 171K
54: R33 Fair Value Measurements (Tables) HTML 116K
55: R34 Commitments and Contingencies (Tables) HTML 41K
56: R35 Description of Business (Details Textual) HTML 61K
57: R36 Summary of Significant Accounting Policies HTML 41K
(Details Textual)
58: R37 Acquisition of Abbreviated New Drug Applications HTML 27K
From Sandoz (Details)
59: R38 Acquisition of Abbreviated New Drug Applications HTML 34K
From Sandoz (Details Textual)
60: R39 Acquisition of Abbreviated New Drug Application HTML 38K
From Laurus Labs (Details Textual)
61: R40 Investment in Equity Securities (Details) HTML 29K
62: R41 Investment in Equity Securities (Details Textual) HTML 41K
63: R42 Property and Equipment (Details) HTML 36K
64: R43 Property and Equipment (Details Textual) HTML 29K
65: R44 Intangible Assets (Details) HTML 33K
66: R45 Intangible Assets (Details 1) HTML 36K
67: R46 Intangible Assets (Details Textual) HTML 23K
68: R47 Establishment of Casi Wuxi (Details Textual) HTML 34K
69: R48 Note Payable (Details Textual) HTML 35K
70: R49 Stockholders' Equity (Details) HTML 46K
71: R50 Stockholders' Equity (Details Textual) HTML 133K
72: R51 Employee Retirement Plan (Details Textual) HTML 25K
73: R52 Stock-Based Compensation (Details) HTML 31K
74: R53 Stock-Based Compensation (Details 1) HTML 35K
75: R54 Stock-Based Compensation (Details 2) HTML 70K
76: R55 Stock-Based Compensation (Details 3) HTML 61K
77: R56 Stock-Based Compensation (Details Textual) HTML 60K
78: R57 Income Taxes (Details) HTML 29K
79: R58 Income Taxes (Details 1) HTML 43K
80: R59 Income Taxes (Details 2) HTML 52K
81: R60 Income Taxes (Details 3) HTML 32K
82: R61 Income Taxes (Details Textual) HTML 45K
83: R62 Fair Value Measurements (Details) HTML 34K
84: R63 Fair Value Measurements (Details 1) HTML 32K
85: R64 Fair Value Measurements (Details Textual) HTML 27K
86: R65 Related Party Transactions (Details Textual) HTML 50K
87: R66 Commitments and Contingencies (Details) HTML 35K
88: R67 Commitments and Contingencies (Details Textual) HTML 57K
90: XML IDEA XML File -- Filing Summary XML 148K
89: EXCEL IDEA Workbook of Financial Reports XLSX 86K
16: EX-101.INS XBRL Instance -- casi-20181231 XML 2.33M
18: EX-101.CAL XBRL Calculations -- casi-20181231_cal XML 125K
19: EX-101.DEF XBRL Definitions -- casi-20181231_def XML 850K
20: EX-101.LAB XBRL Labels -- casi-20181231_lab XML 954K
21: EX-101.PRE XBRL Presentations -- casi-20181231_pre XML 971K
17: EX-101.SCH XBRL Schema -- casi-20181231 XSD 180K
91: ZIP XBRL Zipped Folder -- 0001144204-19-016832-xbrl Zip 167K
Exhibit 21
Subsidiaries of the Registrant
CASI Pharmaceuticals (Beijing) Co., Ltd. (also known as CASI (Beijing) Biopharmaceuticals Technology Co., Ltd.), a company of limited liability, incorporated and existing under the laws of the People’s Republic of China
Beijing Zhongbai Biotechnology Co., Ltd. (also known as Beijing Zhongbio Therapeutics, Ltd.), a company of limited liability, incorporated and existing under the laws of the People’s Republic of China
Miikana Therapeutics, Inc., incorporated in Delaware
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/28/22 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/21 104:11M Toppan Merrill Bridge/FA 3/30/21 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/20 109:13M Toppan Merrill Bridge/FA |